Press Releases

Date Title and Summary View
Toggle Summary Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
View HTML
Toggle Summary Zosano Pharma, Inc. Announces Key Strategic Hire
Seasoned Business Development Executive Chris Krueger Joins as Chief Business Officer
View HTML
Toggle Summary Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis
Asahi Kasei Pharma Obtains Exclusive Rights in Osteoporosis in Japan, China, Korea and Taiwan (Asia)
View HTML
Toggle Summary Zosano Pharma, Inc. To Present At The 14Th Annual Drug Delivery Partnerships Meeting..
Zosano Pharma, Inc. To Present At The 14Th Annual Drug Delivery Partnerships Meeting.. Fremont, Calif. January 20, 2010 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced that Dr.
View HTML
Toggle Summary Zosano Pharma, Inc. Announces Publication of Positive Phase 2 Study of its ZP-PTH Patch for Osteo.
Zosano Pharma, Inc. Announces Publication of Positive Phase 2 Study of its ZP-PTH Patch for Osteo. Zosano Pharma, Inc. is a privately held pharmaceutical company focusing on the development of its lead clinical program, the ZP-PTH rapid delivery patch for the treatment of osteoporosis.  ZP-PTH
View HTML
Toggle Summary Zosano Pharma, Inc. Secures $30 Million In New Round Of Financing
Funds to Support Late-stage Development of ZP-PTH for Osteoporosis
View HTML
Toggle Summary ZOSANO PHARMA, INC. ANNOUNCES APPOINTMENT OF THORSTEN VON STEIN AS CHIEF MEDICAL OFFICER
ZOSANO PHARMA, INC. ANNOUNCES APPOINTMENT OF THORSTEN VON STEIN AS CHIEF MEDICAL OFFICER Fremont, Calif. – June 11, 2009 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced that Thorsten
View HTML
Toggle Summary ZOSANO PHARMA, INC. ANNOUNCES APPOINTMENT OF THORSTEN VON STEIN AS CHIEF MEDICAL OFFICER
ZOSANO PHARMA, INC. ANNOUNCES APPOINTMENT OF THORSTEN VON STEIN AS CHIEF MEDICAL OFFICER Fremont, Calif. – June 11, 2009 – Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, today announced that Thorsten
View HTML
Toggle Summary ZOSANO PHARMA, INC. PRESENTS POSITIVE PHASE 2 RESULTS OF ITS NEEDLE-FREE OSTEOPOROSIS THERAPY
- Rapid Delivery Transdermal Patch Demonstrates Increase in Lumbar Spine and
 Hip Bone Mineral Density -
View HTML
Toggle Summary ZOSANO PHARMA, INC. TO PRESENT POSITIVE PHASE 2 RESULTS OF ITS TRANSDERMAL PATCH FOR OSTEOPOROSIS
ZOSANO PHARMA, INC. TO PRESENT POSITIVE PHASE 2 RESULTS OF ITS TRANSDERMAL PATCH FOR OSTEOPOROSIS ZOSANO PHARMA, INC. TO PRESENT POSITIVE PHASE 2 RESULTS OF ITS TRANSDERMAL PATCH FOR OSTEOPOROSIS Fremont, Calif. – March 31, 2009 – Zosano Pharma, Inc., a privately held pharmaceutical
View HTML